Replies to post #513 on Relmada Therapeutics Inc. (RLMD)

[TheFinalCD]

$RLMD PR during News Halt on Dec. 04 2024

Relmada Therapeutics Reports That Data Monitoring Committee (DMC) Assessment Indicates That the Phase 3 Reliance II Trial is Futile at its Interim Analysis and is Unlikely to Meet the Primary Efficacy Endpoint with Statistical…

— NuntioBot (@NuntioBot) December 4, 2024